Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 7 | 2022 | 46 | 1.000 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2023 | 10 | 0.470 |
Why?
|
| Hemorrhage | 6 | 2021 | 81 | 0.360 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 35 | 0.360 |
Why?
|
| Heparin | 2 | 2020 | 22 | 0.350 |
Why?
|
| Hemophilia B | 3 | 2020 | 10 | 0.340 |
Why?
|
| Anticoagulants | 2 | 2020 | 87 | 0.330 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 1 | 0.310 |
Why?
|
| Factor VIII | 5 | 2023 | 30 | 0.300 |
Why?
|
| Factor IX | 2 | 2020 | 7 | 0.300 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 21 | 0.300 |
Why?
|
| Thrombophilia | 2 | 2020 | 6 | 0.230 |
Why?
|
| Hemostasis | 2 | 2016 | 9 | 0.230 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 14 | 0.220 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2004 | 15 | 0.220 |
Why?
|
| Hemostatics | 1 | 2023 | 10 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2020 | 31 | 0.200 |
Why?
|
| Sex Chromosome Disorders | 1 | 2022 | 1 | 0.200 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 5 | 0.200 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 10 | 0.190 |
Why?
|
| Humans | 21 | 2023 | 27072 | 0.190 |
Why?
|
| Physical Therapists | 1 | 2021 | 4 | 0.180 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 35 | 0.170 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 4 | 0.170 |
Why?
|
| Serum Albumin | 1 | 2020 | 25 | 0.170 |
Why?
|
| Health Literacy | 1 | 2021 | 108 | 0.160 |
Why?
|
| Adolescent | 6 | 2023 | 2172 | 0.160 |
Why?
|
| Young Adult | 6 | 2023 | 1994 | 0.160 |
Why?
|
| Adult | 10 | 2023 | 7831 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 16 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 12 | 0.150 |
Why?
|
| Joint Diseases | 1 | 2018 | 114 | 0.130 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Albumins | 1 | 2016 | 18 | 0.130 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 181 | 0.130 |
Why?
|
| Child | 4 | 2023 | 1295 | 0.120 |
Why?
|
| Blood Coagulation Factors | 2 | 2006 | 19 | 0.120 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2012 | 637 | 0.110 |
Why?
|
| Autoantibodies | 2 | 2006 | 80 | 0.110 |
Why?
|
| Autoimmune Diseases | 2 | 2006 | 44 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2012 | 810 | 0.110 |
Why?
|
| von Willebrand Factor | 3 | 2023 | 10 | 0.100 |
Why?
|
| Male | 8 | 2023 | 14772 | 0.100 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 56 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 111 | 0.080 |
Why?
|
| Middle Aged | 5 | 2020 | 8923 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 17 | 0.080 |
Why?
|
| Female | 6 | 2023 | 15212 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2008 | 18 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2008 | 37 | 0.070 |
Why?
|
| Liver | 1 | 2008 | 145 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 216 | 0.070 |
Why?
|
| United States | 3 | 2018 | 2035 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 2302 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 7 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 29 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 76 | 0.060 |
Why?
|
| Fever | 1 | 2005 | 34 | 0.060 |
Why?
|
| Pneumonectomy | 1 | 2006 | 77 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 72 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 3 | 0.060 |
Why?
|
| Trophoblasts | 1 | 2004 | 2 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 137 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 348 | 0.060 |
Why?
|
| Quality of Life | 2 | 2020 | 629 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 66 | 0.060 |
Why?
|
| Hemorrhagic Disorders | 1 | 2004 | 1 | 0.060 |
Why?
|
| Paraproteins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Fibrin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Biopolymers | 1 | 2004 | 6 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 117 | 0.060 |
Why?
|
| Autoantigens | 1 | 2004 | 26 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 5 | 0.050 |
Why?
|
| Plasma | 1 | 2023 | 16 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 336 | 0.050 |
Why?
|
| Apoptosis | 1 | 2004 | 213 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 481 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2023 | 40 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1144 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2022 | 10 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 85 | 0.050 |
Why?
|
| Elective Surgical Procedures | 2 | 2012 | 37 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2023 | 641 | 0.050 |
Why?
|
| Hemarthrosis | 1 | 2021 | 20 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 4 | 0.040 |
Why?
|
| Aged | 3 | 2020 | 8997 | 0.040 |
Why?
|
| North America | 1 | 2020 | 41 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 552 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 52 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 420 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 1 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 2 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 9 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 1792 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 3538 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 102 | 0.040 |
Why?
|
| Anxiety | 1 | 2018 | 156 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 24 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 4 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2016 | 11 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 72 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 58 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 333 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2016 | 96 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 891 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 312 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 4777 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 444 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 501 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2016 | 3485 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2011 | 17 | 0.020 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2011 | 7 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 15 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 8 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 2011 | 20 | 0.020 |
Why?
|
| Cell Division | 1 | 2011 | 86 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 46 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 107 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 1778 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 227 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 261 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 301 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 329 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 420 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 1395 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2006 | 6 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 26 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 48 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 19 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2006 | 50 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2006 | 29 | 0.020 |
Why?
|
| Prednisone | 1 | 2006 | 66 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 916 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2005 | 1 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2005 | 20 | 0.010 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 6 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 26 | 0.010 |
Why?
|
| Placenta | 1 | 2004 | 9 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 29 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 300 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 120 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 90 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 363 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 186 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 89 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 245 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 167 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 520 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 222 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 482 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 3642 | 0.010 |
Why?
|